STENOCARE reports first-half results with continued momentum: Q2 sales rise 33% over Q1 with fifth consecutive EBITDA-positive quarter

STENOCARE reported Q2 2026 net sales of DKK 4 million, up 33% sequentially from Q1 2026. EBITDA was positive at DKK 56 thousand, and operating cash flow after financial items was positive at DKK 1.6 million, signaling ongoing progress despite the interim report not being reviewed by auditors.

Analysis

The market-relevant takeaway is not the size of the improvement; it is the direction of financing risk. For a microcap consumer-health/cannabis name, even modest positive cash generation can shift the equity from a dilution story toward an optionality story, which can compress the discount rate investors apply to the next 2-4 quarters. That matters most if the improvement is repeatable, because the first multiple rerating usually comes before earnings are meaningfully large.

The second-order effect is on competitors with weaker balance sheets: if STENOCARE can sustain break-even cash generation, it can preserve shelf space, supplier terms, and distributor relationships while peers remain forced sellers of inventory or equity. But the same mechanism cuts both ways — if the gain is driven by working-capital timing, price increases, or one-off expense deferrals, the result can reverse quickly and leave the stock vulnerable to a sharp mean reversion once the cash conversion normalizes.

Over 1-3 months, the key catalyst is whether management can show a second consecutive quarter of positive operating cash flow without balance-sheet support; over 6-18 months, the real question is whether the company can fund growth internally. The consensus risk is overreading a near-zero EBITDA print as structural inflection. Falsification is straightforward: any return to negative operating cash flow, new financing need, or commentary implying that Q2 benefited from temporary working-capital release rather than durable demand.

Key Decisions for Investors

• No high-conviction position yet: treat STENO as a watchlist name, not a buy, until the next 1-2 quarterly prints confirm that cash generation is repeatable rather than seasonal or working-capital driven.
• If liquidity allows and the stock gaps higher on the release, consider fading the move tactically over the next 1-3 sessions; the risk/reward favors a short-term pullback if the market extrapolates a tiny earnings inflection too aggressively.
• For event-driven exposure, look for a pair trade against a weaker European cannabis/medicinal distribution peer with similar revenue scale but weaker cash balance; the objective is to isolate balance-sheet survivability rather than sector beta.
• Set an alert for any guidance that implies external financing within the next 2-3 quarters; that would invalidate the de-risking thesis and likely re-open dilution overhang.
• If STENO can print a second consecutive quarter of positive operating cash flow, reassess for a small long-only starter position on confirmation, not anticipation; the asymmetry improves only after repeatability is established.